222 related articles for article (PubMed ID: 35562868)
1. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma.
Byrne FL; Olzomer EM; Lolies N; Hoehn KL; Wegner MS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562868
[TBL] [Abstract][Full Text] [Related]
2. Increased glucosylceramide production leads to decreased cell energy metabolism and lowered tumor marker expression in non-cancerous liver cells.
Wegner MS; Schömel N; Olzomer EM; Trautmann S; Olesch C; Byrne FL; Brüne B; Gurke R; Ferreirós N; Weigert A; Geisslinger G; Hoehn KL
Cell Mol Life Sci; 2021 Nov; 78(21-22):7025-7041. PubMed ID: 34626204
[TBL] [Abstract][Full Text] [Related]
3. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1).
Wegner MS; Gruber L; Mattjus P; Geisslinger G; Grösch S
BMC Cancer; 2018 Feb; 18(1):153. PubMed ID: 29409484
[TBL] [Abstract][Full Text] [Related]
4. The sirtuin inhibitor cambinol reduces intracellular glucosylceramide with ceramide accumulation by inhibiting glucosylceramide synthase.
Ishibashi Y; Ito M; Hirabayashi Y
Biosci Biotechnol Biochem; 2020 Nov; 84(11):2264-2272. PubMed ID: 32705968
[TBL] [Abstract][Full Text] [Related]
5. Glucosylceramide in T cells regulates the pathology of inflammatory bowel disease.
Komuro M; Nagane M; Endo R; Nakamura T; Miyamoto T; Niwa C; Fukuyama T; Harashima H; Aihara N; Kamiie J; Suzuki R; Yamashita T
Biochem Biophys Res Commun; 2022 Apr; 599():24-30. PubMed ID: 35168060
[TBL] [Abstract][Full Text] [Related]
6. UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.
Wegner MS; Schömel N; Gruber L; Örtel SB; Kjellberg MA; Mattjus P; Kurz J; Trautmann S; Peng B; Wegner M; Kaulich M; Ahrends R; Geisslinger G; Grösch S
Cell Mol Life Sci; 2018 Sep; 75(18):3393-3410. PubMed ID: 29549423
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.
Salustiano EJ; da Costa KM; Freire-de-Lima L; Mendonça-Previato L; Previato JO
J Biol Chem; 2020 May; 295(19):6457-6471. PubMed ID: 32229586
[TBL] [Abstract][Full Text] [Related]
8. Cell-specific in vivo functions of glycosphingolipids: lessons from genetic deletions of enzymes involved in glycosphingolipid synthesis.
Jennemann R; Gröne HJ
Prog Lipid Res; 2013 Apr; 52(2):231-48. PubMed ID: 23473748
[TBL] [Abstract][Full Text] [Related]
9. Glucosylceramide synthase and glycosphingolipid synthesis.
Ichikawa S; Hirabayashi Y
Trends Cell Biol; 1998 May; 8(5):198-202. PubMed ID: 9695839
[TBL] [Abstract][Full Text] [Related]
10. Glycosphingolipid Biosynthesis Pathway in the Spinal Cord and Dorsal Root Ganglia During Inflammatory Pain: Early and Late Changes in Expression Patterns of Glycosyltransferase Genes.
Morita M; Watanabe S; Oyama M; Iwai T; Tanabe M
Neuroscience; 2020 Jan; 428():217-227. PubMed ID: 31917338
[TBL] [Abstract][Full Text] [Related]
11. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells.
Schömel N; Gruber L; Alexopoulos SJ; Trautmann S; Olzomer EM; Byrne FL; Hoehn KL; Gurke R; Thomas D; Ferreirós N; Geisslinger G; Wegner MS
Sci Rep; 2020 May; 10(1):8182. PubMed ID: 32424263
[TBL] [Abstract][Full Text] [Related]
12. A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate.
Cas MD; Casati S; Roda G; Pablo Sardi S; Paroni R; di Fonzo A; Trinchera M
Glycobiology; 2023 Mar; 33(2):88-94. PubMed ID: 36504340
[TBL] [Abstract][Full Text] [Related]
13. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice.
Saadat L; Dupree JL; Kilkus J; Han X; Traka M; Proia RL; Dawson G; Popko B
Glia; 2010 Mar; 58(4):391-8. PubMed ID: 19705459
[TBL] [Abstract][Full Text] [Related]
14. Changes in glycosphingolipid composition during differentiation of human embryonic stem cells to ectodermal or endodermal lineages.
Liang YJ; Yang BC; Chen JM; Lin YH; Huang CL; Cheng YY; Hsu CY; Khoo KH; Shen CN; Yu J
Stem Cells; 2011 Dec; 29(12):1995-2004. PubMed ID: 21956927
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Modulation of Glycosphingolipid Metabolism.
Inokuchi JI; Ode T; Hara-Yokoyama M
Methods Mol Biol; 2018; 1804():401-410. PubMed ID: 29926420
[TBL] [Abstract][Full Text] [Related]
16. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.
Stathem M; Marimuthu S; O'Neal J; Rathmell JC; Chesney JA; Beverly LJ; Siskind LJ
J Cell Biochem; 2015 Jan; 116(1):67-80. PubMed ID: 25145677
[TBL] [Abstract][Full Text] [Related]
17. Interruption of glycosphingolipid synthesis enhances osteoarthritis development in mice.
Seito N; Yamashita T; Tsukuda Y; Matsui Y; Urita A; Onodera T; Mizutani T; Haga H; Fujitani N; Shinohara Y; Minami A; Iwasaki N
Arthritis Rheum; 2012 Aug; 64(8):2579-88. PubMed ID: 22391889
[TBL] [Abstract][Full Text] [Related]
18. Role of Intracellular Lipid Logistics in the Preferential Usage of Very Long Chain-Ceramides in Glucosylceramide.
Yamaji T; Horie A; Tachida Y; Sakuma C; Suzuki Y; Kushi Y; Hanada K
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775668
[TBL] [Abstract][Full Text] [Related]
19. Glycosphingolipid synthesis in cerebellar Purkinje neurons: roles in myelin formation and axonal homeostasis.
Watanabe S; Endo S; Oshima E; Hoshi T; Higashi H; Yamada K; Tohyama K; Yamashita T; Hirabayashi Y
Glia; 2010 Aug; 58(10):1197-207. PubMed ID: 20544855
[TBL] [Abstract][Full Text] [Related]
20. Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues.
Zhu J; Wang Y; Yu Y; Wang Z; Zhu T; Xu X; Liu H; Hawke D; Zhou D; Li Y
Liver Int; 2014 Jan; 34(1):147-60. PubMed ID: 23902602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
